American Society of Clinical Oncology (ASCO)

Updated results of the DAP-HER-01 trial continue to show promising efficacy and manageable toxicity with the oral chemotherapy-free dalpiciclib plus pyrotinib in patients with HER2-positive advanced breast cancer, including the difficult-to-treat subgroups of hormone receptor–negative disease or brain metastases. Read More ›

The phase 2 KAN-HER2 MRD trial will evaluate the addition of neratinib to standard trastuzumab emtansine in patients with HER2-positive breast cancer and evidence of molecular residual disease. Read More ›

Results of a large multicenter retrospective study confirmed that tucatinib in combination with trastuzumab and capecitabine was efficacious in patients with HER2-positive metastatic breast cancer with previous exposure to trastuzumab deruxtecan. Read More ›

Interim results from the Asia cohort of the HER2 REAL study found heterogeneous treatment patterns among patients with HER2-positive unresectable locally advanced or metastatic breast cancer progressing on HER2-directed therapies. Read More ›

Updated results of the phase 2 PERMEATE trial confirmed that pyrotinib plus capecitabine provided long-term survival benefit in patients with HER2-positive metastatic breast cancer and brain metastases. Read More ›

The phase 3 HER2CLIMB-05 trial is evaluating tucatinib plus trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive locally advanced or metastatic breast cancer. Read More ›

Updated results of the phase 3 randomized PRECIOUS trial demonstrated that dual HER2 blockade with pertuzumab re-treatment in combination with trastuzumab plus chemotherapy led to significant overall survival improvement compared with trastuzumab plus chemotherapy in patients previously treated with pertuzumab-containing regimens for HER2-positive locally advanced/metastatic breast cancer, but potential imbalances in chemotherapy during and after the study treatment period may have impacted the results. Read More ›

DESTINY-Breast04 is the first trial comparing outcomes with trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients with HER2-low metastatic breast cancer treated with 1 or 2 prior lines of chemotherapy. Read More ›

Updated data from the EMBER trial of imlunestrant, a new oral selective estrogen receptor degrader showing sustained inhibition of estrogen receptor (ER)-dependent gene transcription and cell proliferation, have been released. Read More ›

Capivasertib plus fulvestrant’s PFS advantage benefitted a broader patient population, and overall survival (OS) data with improved biomarker analyses can now be reported. Read More ›